People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. | — | Pharmaceuticals | Series A | $12.2M | $43.4M | 2023 |
Roy Freeman M.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Roy Freeman M.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dennis Berman | 1 | 2 |
| Milton H. Werner | 1 | 2 |
| Garth H. Lees-Rolfe | 1 | 2 |
| Paul H. Grint | 1 | 1 |
| Gisele H. Dion | 1 | 1 |
| Roy H. Freeman | 1 | 1 |
| Dennis H. Berman | 1 | 1 |
| Joseph Frattaroli, C.P.A. | 1 | 1 |
| Paul Grint, M.D. | 1 | 1 |
| Milton H. Werner Ph.D | 1 | 1 |
| Gisele Dion | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.